Folfox+Irinotecan+Chemort In Esophageal Cancer

In this research study, is studying how Liposomal Irinotecan in combination with the standard of care interventions FOLFOX, carboplatin paclitaxel, and radiation therapy affect gastroesophageal junction or esophagogastric cancer This research study involves the following study intervention: \- Liposomal irinotecan

Trial Details

NCT ID
NCT04656041
Phase
PHASE2
Sponsor
Massachusetts General Hospital
Status
RECRUITING
Cancer Type
Adenocarcinoma Esophageal Cancer
Interventions
  • FOLFOX/ nal-IRI
  • Paclitaxel
  • Carboplatin
  • Proton Radiation Therapy
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Newton, Massachusetts, United States|42.33704,-71.20922

Key Eligibility Criteria

  • Participants must meet all the following criteria in order to be eligible to participate in the study:
  • Histologically or cytologically confirmed T 3/4 or N+ (\> 1 cm in size or FDG avid) Siewart 1-3 gastroesophageal (GE) junction or esophagogastric c…
  • Age 18 years or older. There will be no upper age restriction.
  • ECOG performance status ≤ 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Esophageal Cancer Trials on Trialify →